Johnson & Johnson

05/18/2022 | Press release | Distributed by Public on 05/18/2022 07:45

New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab